Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma Journal Article
| Authors: | Al-Ahmadie, H. A.; Iyer, G.; Janakiraman, M.; Lin, O.; Heguy, A.; Tickoo, S. K.; Fine, S. W.; Gopalan, A.; Chen, Y. B.; Balar, A.; Riches, J.; Bochner, B.; Dalbagni, G.; Bajorin, D. F.; Reuter, V. E.; Milowsky, M. I.; Solit, D. B. |
| Article Title: | Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma |
| Abstract: | FGFR3 mutations are common in low-grade urothelial carcinoma and represent a potential therapeutic target in this disease. Their incidence and functional role in high-grade urothelial carcinoma (HGUC), which displays an increased propensity for recurrence and muscularis propria invasion, is less well defined. We developed a mass spectrometry-based genotyping assay to define the incidence of FGFR3 mutations in a large clinically annotated set of urothelial carcinomas. FGFR3 mutations were found in 17% of HGUC versus 84% of low-grade lesions. Retrospective pathological review of the class of FGFR3 mutant HGUC revealed unique histological features, characterized by a bulky, exophytic component with branching papillary architecture as well as irregular nuclei with a koilocytoid appearance. The predictive value of this histological appearance was confirmed using a prospective set of 49 additional HGUCs. Prospective histological review was able to correctly predict for the presence of an FGFR3 mutation in 13/24 HGUC specimens that exhibited the distinct morphology (54%). All 25 specimens lacking the defined histological features were FGFR3 wild-type for a negative predictive value of 100%. Macrodissection of individual tumours confirmed the presence of the FGFR3 mutant allele in non-invasive and invasive, low and high-grade regions of individual tumours and in the lymph node metastases of patients whose tumours possessed the characteristic morphological signature, suggesting that FGFR3 mutations are not restricted to the more clinically indolent regions of HGUCs. These data suggest that histological screening of HGUCs followed by confirmatory genotyping can be used to enrich for the population of HGUCs most likely to harbour activating mutations in the FGFR-3 receptor tyrosine kinase. Histological review could thus aid in the development of targeted inhibitors of FGFR-3 by facilitating the identification of the subset of patients most likely to harbour activating mutations in the FGFR3 gene. © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
| Keywords: | human tissue; somatic mutation; histopathology; lymph node metastasis; cancer grading; genotype; fibroblast growth factor receptor 3; morphology; urothelial carcinoma; matrix assisted laser desorption ionization time of flight mass spectrometry; transitional cell carcinoma; fgfr-3; fibroblast growth factor receptor-3 |
| Journal Title: | Journal of Pathology |
| Volume: | 224 |
| Issue: | 2 |
| ISSN: | 0022-3417 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2011-06-01 |
| Start Page: | 270 |
| End Page: | 279 |
| Language: | English |
| DOI: | 10.1002/path.2892 |
| PROVIDER: | scopus |
| PUBMED: | 21547910 |
| PMCID: | PMC3235805 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 23 June 2011" - "CODEN: JPTLA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work